Aliases & Classifications for Pulmonary Tuberculosis

MalaCards integrated aliases for Pulmonary Tuberculosis:

Name: Pulmonary Tuberculosis 12 14
Tuberculosis, Pulmonary 42 69
Tuberculosis Pulmonary 52
Ptb 45

Classifications:



External Ids:

Disease Ontology 12 DOID:2957
ICD10 33 A15 A15.0
ICD9CM 35 011 011.9 011.90
MeSH 42 D014397
NCIt 47 C26899
UMLS 69 C0041327

Summaries for Pulmonary Tuberculosis

Disease Ontology : 12 A tuberculosis that is a contagious disease located in lungs. The infection has symptom fever, has symptom cough, has symptom difficulty in breathing, has symptom inflammatory infiltrations, has symptom formation of tubercles, has symptom caseation, has symptom pleural effusion, and has symptom fibrosis.

MalaCards based summary : Pulmonary Tuberculosis, also known as tuberculosis, pulmonary, is related to cryptococcosis and epidermolysis bullosa acquisita, and has symptoms including hemoptysis An important gene associated with Pulmonary Tuberculosis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Priftin and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Pulmonary Tuberculosis

Diseases related to Pulmonary Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
id Related Disease Score Top Affiliating Genes
1 cryptococcosis 30.5 HLA-DRB1 IL10 TNF
2 epidermolysis bullosa acquisita 30.2 HLA-DRB1 IFNG IL10
3 melioidosis 29.8 IFNG IL10 IL18 TLR2 TNF
4 steatorrhea 29.6 ADA IFNG IL18 TNF
5 lymphoma 29.4 IFNG IL10 IL2 IL4 TLR9 TNF
6 hypervitaminosis d 29.2 IFNG IL10 IL4 TLR2 TLR9 TNF
7 rheumatoid arthritis 28.6 HLA-DRB1 IFNG IL10 IL18 IL2 IL4
8 systemic lupus erythematosus 28.1 HLA-DRB1 IFNG IL10 IL18 IL2 IL4
9 asthma 28.0 ADA HLA-DRB1 IFNG IL10 IL18 IL4
10 laryngeal tuberculosis 11.1
11 tuberculosis 11.0
12 pure autonomic failure 10.9 IL10 TNF
13 scirrhous adenocarcinoma 10.9 IL2 TNF
14 myoclonic astatic epilepsy 10.9 IFNG IL4
15 mosaic trisomy 1 10.8 HLA-DRB1 IFNG TNF
16 nosophobia 10.8
17 autoimmune polyglandular syndrome type 3 10.8 IFNG IL2 TNF
18 ethmoid sinus cancer 10.8 IFNG SLC11A1 VDR
19 intracranial aneurysms multiple congenital anomaly 10.8 IFNG IFNGR1
20 senile reticular retinal degeneration 10.8 IFNG IL10 TNF
21 psychologic dyspareunia 10.8 IFNG IL10 TNF
22 dysphagia 10.8 IFNG IL10 TNF
23 amyotrophic lateral sclerosis type 10 10.8 IFNG IL2 TNF
24 sternal cleft 10.8 IFNG TNF
25 conduct disorder 10.8 IFNG IL10 TNF
26 anthracosilicosis 10.8 HLA-DRB1 IFNG IL2
27 bulbospinal polio 10.8 IFNG IL2
28 papillary squamous carcinoma 10.8 HLA-DRB1 IFNG IL10
29 parametritis 10.7 IFNG IL2 TNF
30 acute ackee fruit intoxication 10.7 IL10 IL4 TNF
31 eye accommodation disease 10.7 IFNG IL10 IL4
32 prothrombin thrombophilia 10.7 MBL2 TLR2
33 graft-versus-host disease, protection against 10.7 IFNG IL10 IL2
34 bolivian hemorrhagic fever 10.7 IFNG IL2 TNF
35 basidiobolomycosis 10.7 IL10 IL4 TNF
36 lagophthalmos 10.7 IL10 IL4 TNF
37 thelaziasis 10.7 IFNG IL10 IL4
38 aseptic meningitis 10.7 HLA-DRB1 TLR2 TNF
39 primary biliary cirrhosis 10.7 IL10 SLC11A1 TNF
40 pityriasis rosea 10.7 TLR2 TNF VDR
41 chronic graft versus host disease 10.7 IFNG IL10 IL2
42 liver leiomyoma 10.7 IL10 IL4 TNF
43 moderately severe hemophilia b 10.7 HLA-DRB1 IL10 TNF
44 cornea cancer 10.7 IFNG IL10 TNF
45 plummer's disease 10.7 HLA-DRB1 IL10 TNF
46 megaloblastic anemia 10.7 IL10 TLR2 TNF
47 vacterl association 10.7 IL10 TNF VDR
48 burn scar 10.7 IFNG IL10 TNF
49 x-linked intellectual disability, van esch type 10.7 IFNG IL2 IL4
50 tabatznik syndrome 10.7 IL18 TNF

Comorbidity relations with Pulmonary Tuberculosis via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchiectasis
Bronchitis Deficiency Anemia
Heart Disease Iron Deficiency Anemia
Pleural Tuberculosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Pulmonary Tuberculosis:



Diseases related to Pulmonary Tuberculosis

Symptoms & Phenotypes for Pulmonary Tuberculosis

UMLS symptoms related to Pulmonary Tuberculosis:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Tuberculosis:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 IFNG IFNGR1 IL10 IL12RB1 IL18 IL2
2 homeostasis/metabolism MP:0005376 10.39 TLR9 TNF VDR ADA HP IFNG
3 immune system MP:0005387 10.36 TLR9 TNF VDR ADA HP IFNG
4 digestive/alimentary MP:0005381 10.34 ADA IFNG IFNGR1 IL10 IL18 IL2
5 cardiovascular system MP:0005385 10.33 INHA P2RX7 TLR2 TNF VDR ADA
6 cellular MP:0005384 10.31 HP IFNG IFNGR1 IL10 IL18 IL2
7 behavior/neurological MP:0005386 10.26 IL10 IL12RB1 IL18 IL2 P2RX7 TLR2
8 growth/size/body region MP:0005378 10.24 ADA IFNG IL10 IL18 IL2 IL4
9 endocrine/exocrine gland MP:0005379 10.21 IL2 IL4 INHA TLR2 TNF VDR
10 mortality/aging MP:0010768 10.17 TLR2 TLR9 TNF VDR ADA HP
11 liver/biliary system MP:0005370 10.07 ADA HP IFNG IFNGR1 IL10 IL2
12 integument MP:0010771 10.06 VDR IFNG IFNGR1 IL10 IL18 IL4
13 neoplasm MP:0002006 9.91 HP IFNG IFNGR1 IL10 IL2 INHA
14 renal/urinary system MP:0005367 9.81 ADA HP IFNG IFNGR1 IL4 MBL2
15 reproductive system MP:0005389 9.65 ADA IFNG IFNGR1 IL10 IL2 IL4
16 skeleton MP:0005390 9.32 ADA IFNG IFNGR1 IL10 IL4 INHA

Drugs & Therapeutics for Pulmonary Tuberculosis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Priftin 17 RIFAPENTINE Hoechst Marion Roussel June 1998

Drugs for Pulmonary Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
2
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1 74-55-5 3279 14052
3
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
4
Isoniazid Approved Phase 4,Phase 3,Phase 2,Phase 1 54-85-3 3767
5
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 354812-41-2, 151096-09-2 152946
6
Norgestimate Approved Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
7
Pyrazinamide Approved Phase 4,Phase 3,Phase 2,Phase 1 98-96-4 1046
8
Rifabutin Approved Phase 4,Phase 2 72559-06-9 6323490
9
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
10
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 1 57-92-1 19649
11
Calcium Carbonate Approved Phase 4,Phase 3 471-34-1
12
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
13
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
14
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
16
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
21 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1
24 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2,Phase 1
25 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
26 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
27 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1
28 Estradiol valerate Phase 4,Phase 3,Phase 2,Phase 1 979-32-8
29 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2,Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Polyestradiol phosphate Phase 4,Phase 3,Phase 2,Phase 1
34 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
36 Ergocalciferols Phase 4,Phase 3,Phase 2
37 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
38 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
39 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
40 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
41 Adrenergic Agents Phase 4,Phase 3
42 Adrenergic Agonists Phase 4,Phase 3
43 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3
44 Adrenergic beta-Agonists Phase 4,Phase 3
45 Anti-Asthmatic Agents Phase 4,Phase 3
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
47 Autonomic Agents Phase 4,Phase 3
48 Bromides Phase 4
49 Bronchodilator Agents Phase 4,Phase 3
50 Cholinergic Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 305)

id Name Status NCT ID Phase Drugs
1 Research on New Regimens for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
2 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
3 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis Unknown status NCT02464683 Phase 4
4 Simple Verbal Intervention for Adequately Collecting Sputum Unknown status NCT01135043 Phase 4
5 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
6 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
7 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
8 Improving Community Based Tuberculosis Care in Ethiopia Completed NCT00803322 Phase 4
9 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4 Levofloxacin
10 The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis Completed NCT00939419 Phase 4
11 Ultrathin Bronchoscopy for Solitary Pulmonary Nodules Completed NCT02490059 Phase 4
12 Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea Completed NCT00864812 Phase 4 tiotropium with fluticasone propionate/salmeterol (FSC);tiotropium
13 QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Completed NCT01223534 Phase 4 Preventive treatment with Isoniazid.;Preventive treatment with Isoniazid
14 Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis Recruiting NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
15 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation Recruiting NCT02231229 Phase 4 conventional therapy
16 Treating Tuberculosis Wasting With a High-protein Supplement Recruiting NCT03302949 Phase 4
17 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis Not yet recruiting NCT02169570 Phase 4
18 Prevention of Tuberculosis in Prisons Not yet recruiting NCT03028129 Phase 4 Isoniazid 900 milligrams;Placebo
19 Latency in Pulmonary Tuberculosis Unknown status NCT01154959 Phase 3 Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
20 Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients Unknown status NCT00698386 Phase 3
21 Pulmonary Tuberculosis and Vitamin D Unknown status NCT00507000 Phase 3 Cholecalciferol;Lactose granules
22 A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216385 Phase 3 Gatifloxacin combined regimen
23 Development of Tuberculosis Diagnostic Kit Unknown status NCT00311207 Phase 3
24 Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Unknown status NCT01398618 Phase 3 4-month rifampin vs. 9-month isoniazid
25 Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis Unknown status NCT00376012 Phase 3 Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide);Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
26 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
27 L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) Completed NCT00677339 Phase 3 L-arginine;Vitamin D;Placebo L-arginine;Placebo Vitamin D
28 Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis Completed NCT00864383 Phase 3 Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
29 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. Completed NCT00341328 Phase 3
30 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients Completed NCT00265226 Phase 3
31 Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis Completed NCT00801606 Phase 3 Zinc;Micronutrient without zinc;Micronutrient with zinc;Placebo
32 A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients Completed NCT00366470 Phase 3 A. 100,000 IU Cholecalciferol per dose of 3.3ml
33 Nutrition, Diabetes and Pulmonary TB/HIV Completed NCT00311298 Phase 3
34 TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis Completed NCT00023335 Phase 3 Rifapentine;Isoniazid
35 Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis Completed NCT01517022 Phase 3 nicotine replacement therapy
36 Tuberculosis Treatment Shortening Trial Completed NCT00130247 Phase 3 Pyrazinamide;Rifampin;Isoniazid;Ethambutol
37 Vitamin A Therapy for Tuberculosis Completed NCT00057434 Phase 3 multivitamin
38 Trial of Adjunctive Vitamin D in Tuberculosis Treatment Completed NCT00419068 Phase 3 Cholecalciferol;Migliol Placebo Oil
39 Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Completed NCT01061593 Phase 3
40 The Treatment of Tuberculosis in HIV-Infected Patients Completed NCT00001033 Phase 3 Ethambutol hydrochloride;Isoniazid;Pyrazinamide;Pyridoxine hydrochloride;Levofloxacin;Rifampin
41 High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
42 Treatment Duration for Abdominal Tuberculosis Completed NCT01124929 Phase 3 RNTCP Category I treatment for 6 months;RNTCP Category I treatment for 9months
43 A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients Completed NCT00398996 Phase 3 Early versus intermediate versus late initiation of ART
44 Indacaterol EfectIveness In COPD Patients With Tuberculosis History Completed NCT01778062 Phase 3 Indacaterol;Control
45 Optimization of the TB Treatment Regimen Cascade Completed NCT02153528 Phase 3 double rimfampicin;Standard TB treatment
46 Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis Completed NCT01424670 Phase 3 Delamanid;Placebo;Optimized Background Regimen (OBR);Antiretrovirals (ARVs)
47 Tuberculosis Prevention for HIV Infected Adults Completed NCT00057122 Phase 3 Isoniazid;Rifapentine;Rifampin
48 Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis Recruiting NCT02467608 Phase 2, Phase 3 Isoniazid with HUEXC030 and RZE;HRZE
49 A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis Recruiting NCT02581527 Phase 3 Rifampicin 1200mg;Rifampicin 1800mg;4FDC
50 A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis Recruiting NCT02333799 Phase 3 Bedaquiline;PA-824;Linezolid

Search NIH Clinical Center for Pulmonary Tuberculosis

Cochrane evidence based reviews: tuberculosis, pulmonary

Genetic Tests for Pulmonary Tuberculosis

Anatomical Context for Pulmonary Tuberculosis

MalaCards organs/tissues related to Pulmonary Tuberculosis:

39
Lung, Testes, T Cells, Skin, Monocytes, Liver, Whole Blood

Publications for Pulmonary Tuberculosis

Articles related to Pulmonary Tuberculosis:

(show top 50) (show all 1299)
id Title Authors Year
1
Addison's Disease Caused by Tuberculosis with Atypical Hyperpigmentation and Active Pulmonary Tuberculosis. ( 28717080 )
2017
2
Association study of the FTO gene polymorphisms with the risk of pulmonary tuberculosis in a sample of Iranian population. ( 28357924 )
2017
3
Serum amyloid A, protein Z, and C4b-binding protein I^ chain as new potential biomarkers for pulmonary tuberculosis. ( 28278182 )
2017
4
Trace elements in blood samples of smoker and nonsmoker active pulmonary tuberculosis patients from Jamshoro, Pakistan. ( 28948455 )
2017
5
Pulmonary tuberculosis presenting as post-operative fever of unknown origin. ( 28062417 )
2017
6
Evaluation of the TB-LAMP assay for the rapid diagnosis of pulmonary tuberculosis in Northern India. ( 28911360 )
2017
7
Optic perineuritis simultaneously associated with active pulmonary tuberculosis without intraocular tuberculosis. ( 28944211 )
2017
8
Sonographic Findings of Abdominal Tuberculosis in Children with Pulmonary Tuberculosis. ( 28333710 )
2017
9
Effect of a brief smoking cessation intervention on adult tobacco smokers with pulmonary tuberculosis: A cluster randomized controlled trial from North India. ( 28928319 )
2017
10
IL-10 -1082 A>G (rs1800896) Polymorphism Confers Susceptibility to Pulmonary Tuberculosis in Caucasians But not in Asians and Africans: A Meta-Analysis. ( 28951522 )
2017
11
Drug resistance patterns among extra-pulmonary tuberculosis cases in a tertiary care centre in North India. ( 28911354 )
2017
12
Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence. ( 28934422 )
2017
13
The incidence of subclinical forms of urogenital tuberculosis in patients with pulmonary tuberculosis. ( 28757299 )
2017
14
Diagnostic accuracy of a selected signature gene set that discriminates active pulmonary tuberculosis and other pulmonary diseases. ( 28941629 )
2017
15
CT findings of pulmonary tuberculosis and tuberculous pleurisy in diabetes mellitus patients. ( 28185999 )
2017
16
Comprehensive understanding of health-seeking behaviour among pulmonary tuberculosis patients in China. ( 28911351 )
2017
17
A comparison of 18F-FDG PET/MR with PET/CT in pulmonary tuberculosis. ( 28885539 )
2017
18
Ready experimental translocation of Mycobacterium canettii yields pulmonary tuberculosis. ( 28923895 )
2017
19
Light-emitting diode fluorescent microscopy and Xpert MTB/RIFAr assay for diagnosis of pulmonary tuberculosis among patients attending Ambo hospital, west-central Ethiopia. ( 28893193 )
2017
20
Population-Based Case-Control Study Assessing the Association between Statins Use and Pulmonary Tuberculosis in Taiwan. ( 28912719 )
2017
21
Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis. ( 28902922 )
2017
22
Profiling dendritic cell subsets in the patients with active pulmonary tuberculosis. ( 28889065 )
2017
23
Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease. ( 28416955 )
2017
24
Stool culture for the diagnosis of pulmonary tuberculosis in children. ( 28904186 )
2017
25
Disseminated Nocardiosis in renal transplant recipient under therapy for pulmonary tuberculosis: a case report. ( 28159010 )
2017
26
Pulmonary tuberculosis diagnostic practices among people living with the human immunodeficiency virus in Lesotho. ( 28911357 )
2017
27
Evaluation of Xpert MTB/RIF testing for rapid diagnosis of childhood pulmonary tuberculosis in children by Xpert MTB/RIF testing of stool samples in a low resource setting. ( 28886729 )
2017
28
Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks. ( 28065665 )
2017
29
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. ( 28076011 )
2017
30
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( 28947041 )
2017
31
Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis. ( 28911359 )
2017
32
Hematological and Biochemistry Profile and Risk Factors Associated with Pulmonary Tuberculosis Patients in Guyana. ( 27190646 )
2016
33
Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality. ( 27609755 )
2016
34
P2X7R Gene Polymorphisms are Associated with Increased Risk of Pulmonary Tuberculosis in the Tibetan Chinese Population. ( 27672203 )
2016
35
Relation between smear positivity and imaging findings in children with pulmonary tuberculosis. ( 28043529 )
2016
36
High Beclin-1 Expression in Human Alveolar Macrophage Significantly Correlate with the Bacteriologic Sterilization in Pulmonary Tuberculosis Patients. ( 27468561 )
2016
37
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. ( 27159505 )
2016
38
Carcinomatous pleuritis and pericarditis accompanied by pulmonary tuberculosis. ( 28031837 )
2016
39
Association of polymorphisms of the transporter associated with antigen processing (TAP2) gene with pulmonary tuberculosis in an elderly Japanese population. ( 27325005 )
2016
40
Efficacy and safety of quercetin and polyvinylpyrrolidone in treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy. ( 28043493 )
2016
41
Susceptibility to pulmonary tuberculosis: host genetic deficiency in tumor necrosis factor alpha (TNF-I+) gene and tumor necrosis factor receptor 2 (TNFR2). ( 28043509 )
2016
42
Organizing pneumonia and pulmonary tuberculosis: Coexistent or associated diseases. ( 27156206 )
2016
43
Proposed Approach for 4-Month Treatment of Culture-Negative Pulmonary Tuberculosis in Adults. ( 27627478 )
2016
44
Crescentic Glomerulonephritis Associated with Pulmonary Tuberculosis. ( 26894074 )
2016
45
Mortality among pulmonary tuberculosis and HIV-1 co-infected Nigerian children being treated for pulmonary tuberculosis and on antiretroviral therapy: a retrospective cohort study. ( 28053917 )
2016
46
A meta-analysis of P2X7 gene-1513A/C polymorphism and pulmonary tuberculosis susceptibility. ( 26585364 )
2016
47
Alleles of HLA-DRB1*04 Associated with Pulmonary Tuberculosis in Amazon Brazilian Population. ( 26901036 )
2016
48
Chromoblastomycosis due to Fonsecaea monophora misdiagnosed as sporotrichosis and cutaneous tuberculosis in a pulmonary tuberculosis patient. ( 27330937 )
2016
49
Identification potential biomarkers in pulmonary tuberculosis and latent infection based on bioinformatics analysis. ( 27655333 )
2016
50
Delay in diagnosis among pulmonary tuberculosis patients of Rayagada District, Odisha, India. ( 28043535 )
2016

Variations for Pulmonary Tuberculosis

Expression for Pulmonary Tuberculosis

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Tuberculosis patients vs. healthy controls: 35 (show all 44)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GBP6 guanylate binding protein family, member 6 Blood + 4.38 0.000
2 ANKRD22 ankyrin repeat domain 22 Blood + 4.04 0.000
3 PDCD1LG2 programmed cell death 1 ligand 2 Blood + 4.03 0.000
4 RLTPR RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing Blood - 3.89 0.000
5 CD274 CD274 molecule Blood + 3.87 0.000
6 CD248 CD248 molecule, endosialin Blood - 3.84 0.000
7 SPIB Spi-B transcription factor (Spi-1/PU.1 related) Blood - 3.81 0.000
8 LRRN3 leucine rich repeat neuronal 3 Blood - 3.61 0.000
9 LINC00668 long intergenic non-protein coding RNA 668 Blood + 3.60 0.000
10 C1QC complement component 1, q subcomponent, C chain Blood + 3.56 0.000
11 CR1 complement component (3b/4b) receptor 1 (Knops blood group) Blood + 3.54 0.000
12 AEBP1 AE binding protein 1 Blood - 3.53 0.000
13 KREMEN1 kringle containing transmembrane protein 1 Blood + 3.49 0.000
14 CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit Blood + 3.46 0.000
15 LGALSL lectin, galactoside-binding-like Blood - 3.43 0.000
16 BATF2 basic leucine zipper transcription factor, ATF-like 2 Blood + 3.42 0.000
17 PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1 Blood - 3.40 0.000
18 CD22 CD22 molecule Blood - 3.38 0.000
19 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Blood + 3.38 0.000
20 NAIP NLR family, apoptosis inhibitory protein Blood + 3.34 0.000
21 EPHB6 EPH receptor B6 Blood - 3.30 0.000
22 DICER1 dicer 1, ribonuclease type III Blood + 3.26 0.000
23 MVD mevalonate (diphospho) decarboxylase Blood - 3.26 0.000
24 FBLN2 fibulin 2 Blood - 3.26 0.000
25 FBXL16 F-box and leucine-rich repeat protein 16 Blood - 3.23 0.000
26 CR2 complement component (3d/Epstein Barr virus) receptor 2 Blood - 3.21 0.000
27 PRSS33 protease, serine, 33 Blood - 3.21 0.000
28 FGF13 fibroblast growth factor 13 Blood + 3.20 0.000
29 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 Blood - 3.19 0.000
30 RTKN2 rhotekin 2 Blood - 3.19 0.000
31 EPHA1 EPH receptor A1 Blood - 3.16 0.000
32 APOL6 apolipoprotein L, 6 Blood + 3.16 0.000
33 CRIP2 cysteine-rich protein 2 Blood - 3.15 0.000
34 C1QB complement component 1, q subcomponent, B chain Blood + 3.15 0.000
35 CARD17 caspase recruitment domain family, member 17 Blood + 3.14 0.000
36 SERINC5 serine incorporator 5 Blood - 3.12 0.000
37 HKDC1 hexokinase domain containing 1 Blood - 3.11 0.000
38 NT5E 5'-nucleotidase, ecto (CD73) Blood - 3.10 0.000
39 LINC00342 long intergenic non-protein coding RNA 342 Blood + 3.10 0.000
40 PMEPA1 prostate transmembrane protein, androgen induced 1 Blood - 3.09 0.000
41 FCGBP Fc fragment of IgG binding protein Blood - 3.07 0.000
42 SALL2 spalt-like transcription factor 2 Blood - 3.06 0.000
43 GPA33 glycoprotein A33 (transmembrane) Blood - 3.02 0.000
44 SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 Blood - 3.00 0.000
Search GEO for disease gene expression data for Pulmonary Tuberculosis.

Pathways for Pulmonary Tuberculosis

Pathways related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 HLA-DRB1 HP IFNG IFNGR1 IL10 IL12RB1
2
Show member pathways
13.56 IFNG IFNGR1 IL10 IL12RB1 IL18 IL2
3
Show member pathways
13.45 IL10 IL12RB1 IL18 IL2 IL4 TLR2
4
Show member pathways
13.43 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
5
Show member pathways
13.27 HLA-DRB1 IFNG IFNGR1 IL2 IL4 TLR2
6
Show member pathways
12.92 IFNG IFNGR1 IL10 IL2 MBL2 TLR2
7
Show member pathways
12.91 HLA-DRB1 IFNG IL10 IL2 IL4 TNF
8
Show member pathways
12.78 HLA-DRB1 IFNG IFNGR1 IL18 IL2 IL4
9
Show member pathways
12.66 IFNG IL10 IL12RB1 IL18 IL2 TNF
10 12.62 IFNG IL10 IL2 IL4 TLR2 TLR9
11
Show member pathways
12.61 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
12
Show member pathways
12.57 IFNG IFNGR1 IL2 IL4 TNF
13
Show member pathways
12.49 IFNG IL10 IL2 IL4 TNF
14
Show member pathways
12.39 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
15
Show member pathways
12.35 IFNG IL4 TLR2 TNF
16
Show member pathways
12.3 IFNG IFNGR1 IL10 IL12RB1 IL2 IL4
17
Show member pathways
12.29 HLA-DRB1 IFNG IFNGR1 IL10 IL4 TLR2
18 12.27 IFNG IFNGR1 TLR2 TLR9 TNF
19
Show member pathways
12.25 IFNG IFNGR1 IL4 TLR2 TLR9 TNF
20
Show member pathways
12.21 IFNG IL10 IL18 IL2 IL4 TNF
21 12.09 IFNG IL10 IL2 IL4 TNF
22 12.06 IFNG IL2 IL4 TNF
23 12.04 IL10 IL18 IL4 TNF
24
Show member pathways
12.02 IFNG IL12RB1 IL4 TLR2 TLR9
25
Show member pathways
12.02 HLA-DRB1 IFNG IL12RB1 IL18 IL2 IL4
26 11.99 IFNG IFNGR1 IL10 IL12RB1 IL2
27 11.96 HLA-DRB1 IFNG IL18 TLR2 TNF
28 11.95 IFNG IL10 TLR2 TNF
29 11.86 HLA-DRB1 IFNG IFNGR1 IL10 IL18 TLR2
30
Show member pathways
11.85 IFNG IL2 IL4 TNF
31 11.85 IFNG IL10 IL2 TLR9 TNF
32 11.83 IFNG IFNGR1 IL18
33 11.81 IFNG IL2 IL4
34 11.79 IL10 IL4 TLR2 TLR9 TNF
35 11.77 IFNG IL10 IL12RB1 IL18 IL2 IL4
36
Show member pathways
11.69 IFNG IL2 TNF
37
Show member pathways
11.67 IFNG IL2 TNF
38 11.63 HLA-DRB1 IL10 MBL2
39 11.63 IL10 IL18 IL4 TNF
40 11.62 IL18 TLR2 TNF
41 11.62 IFNG IL18 TLR2 TNF
42 11.61 IFNG IL10 IL2 IL4
43 11.59 IFNG IL2 TNF
44
Show member pathways
11.58 IFNG IFNGR1 TNF
45 11.56 IFNG IL2 TNF
46 11.54 IFNG IL10 IL18 TLR2 TLR9 TNF
47
Show member pathways
11.53 IFNG IL10 IL2 TNF
48 11.52 IFNG TNF VDR
49 11.42 IFNG IL18 IL4 TNF
50 11.4 IFNG IL10 IL18 TLR9 TNF

GO Terms for Pulmonary Tuberculosis

Cellular components related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 HP IFNG IL10 IL18 IL2 IL4
2 extracellular space GO:0005615 9.7 ADA HP IFNG IL10 IL18 IL2
3 external side of plasma membrane GO:0009897 9.17 ADA HLA-DRB1 IFNG IL12RB1 IL4 P2RX7

Biological processes related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.97 IFNG IL2 IL4 P2RX7 TNF
2 defense response to Gram-positive bacterium GO:0050830 9.92 MBL2 P2RX7 TLR2 TNF
3 cellular response to organic cyclic compound GO:0071407 9.89 IL18 P2RX7 TNF
4 interferon-gamma-mediated signaling pathway GO:0060333 9.89 HLA-DRB1 IFNG IFNGR1
5 positive regulation of inflammatory response GO:0050729 9.89 IL18 IL2 TLR2 TLR9
6 positive regulation of T cell proliferation GO:0042102 9.88 IFNG IL2 IL4
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IFNG IL18 IL2 IL4
8 positive regulation of tumor necrosis factor production GO:0032760 9.86 IFNG TLR2 TLR9
9 extrinsic apoptotic signaling pathway GO:0097191 9.86 IFNG P2RX7 TNF
10 positive regulation of interleukin-6 production GO:0032755 9.84 P2RX7 TLR2 TLR9 TNF
11 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 IL18 TLR2 TNF
12 positive regulation of phagocytosis GO:0050766 9.82 MBL2 SLC11A1 TNF
13 positive regulation of cytokine secretion GO:0050715 9.82 IL10 P2RX7 TNF
14 positive regulation of interleukin-8 production GO:0032757 9.81 TLR2 TLR9 TNF
15 negative regulation of interleukin-6 production GO:0032715 9.81 IL10 TLR9 TNF
16 positive regulation of interleukin-12 production GO:0032735 9.8 IFNG TLR2 TLR9
17 positive regulation of gene expression GO:0010628 9.8 IFNG P2RX7 SLC11A1 TLR2 TLR9 TNF
18 positive regulation of interleukin-10 production GO:0032733 9.79 IL4 TLR2 TLR9
19 positive regulation of T cell differentiation GO:0045582 9.78 ADA IL2 IL4
20 positive regulation of chemokine production GO:0032722 9.77 TLR2 TLR9 TNF
21 positive regulation of activated T cell proliferation GO:0042104 9.76 IL12RB1 IL18 IL2 IL4
22 response to molecule of bacterial origin GO:0002237 9.74 IL10 TLR2 TLR9
23 positive regulation of interleukin-17 production GO:0032740 9.73 IL18 IL2
24 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.73 IFNG IFNGR1
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 IL10 TNF
26 I-kappaB phosphorylation GO:0007252 9.73 TLR2 TLR9
27 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IFNG IL2 IL4
28 regulation of cytokine secretion GO:0050707 9.72 TLR2 TLR9
29 positive regulation of T cell mediated cytotoxicity GO:0001916 9.72 IL12RB1 P2RX7
30 T-helper 1 type immune response GO:0042088 9.72 HLA-DRB1 IL18
31 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.72 IL18 TLR9
32 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IFNG IL4 TNF
33 positive regulation of T-helper 1 type immune response GO:0002827 9.71 IL12RB1 SLC11A1
34 defense response to protozoan GO:0042832 9.71 IFNG IL10 IL4 SLC11A1
35 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
36 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 IL10 TNF
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IFNG IL10 IL4
38 defense response to bacterium GO:0042742 9.7 HP IFNG IL10 MBL2 SLC11A1 TLR9
39 positive regulation of tissue remodeling GO:0034105 9.69 IL18 IL2
40 negative regulation of interleukin-8 production GO:0032717 9.69 IL10 TLR9
41 positive regulation of B cell proliferation GO:0030890 9.69 ADA IL2 IL4
42 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 IL2 IL4
43 regulation of isotype switching GO:0045191 9.68 IL10 IL4
44 positive regulation of interleukin-18 production GO:0032741 9.67 TLR2 TLR9
45 positive regulation of mononuclear cell migration GO:0071677 9.67 IL4 TNF
46 positive regulation of NF-kappaB import into nucleus GO:0042346 9.67 IL18 TLR2 TLR9 TNF
47 positive regulation of toll-like receptor signaling pathway GO:0034123 9.66 TLR2 TLR9
48 receptor biosynthetic process GO:0032800 9.66 IL10 TNF
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.65 IFNG TNF
50 type 2 immune response GO:0042092 9.65 IL10 IL18 IL4

Molecular functions related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 INHA
2 cytokine activity GO:0005125 9.17 IFNG IL10 IL18 IL2 IL4 INHA

Sources for Pulmonary Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....